Skip to main navigation Skip to search Skip to main content

Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations

  • Public Health Research Institute, New York
  • RBHS-NEW JERSEY MEDICAL SCHOOL
  • University of California at San Francisco
  • University of Michigan, Ann Arbor
  • Purdue University

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB) treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB patients. Recently, several clinical trials of “universal” drug regimens, aiming to treat drug-susceptible and drug-resistant TB, have included a fluoroquinolone. In the absence of clinical data comparing their side-by-side efficacies in controlled MDR-TB trials, a pharmacological rationale is needed to guide the selection of the most efficacious fluoroquinolone. The present studies were designed to test the hypothesis that fluoroquinolone concentrations (pharmacokinetics) and activity (pharmacodynamics) at the site of infection are better predictors of efficacy than the plasma concentrations and potency measured in standard growth inhibition assays and are better suited to determinations of whether one of the fluoroquinolones outperforms the others in rabbits with active TB. We first measured the penetration of these fluoroquinolones in lung lesion compartments, and their potency against bacterial populations that reside in each compartment, to compute lesion-centric pharmacokinetic-pharmacodynamic (PK/PD) parameters. PK modeling methods were used to quantify drug penetration from plasma to tissues at human-equivalent doses. On the basis of these metrics, moxifloxacin emerged with a clear advantage, whereas plasma-based PK/PD favored levofloxacin (the ranges of the plasma AUC/ MIC ratio [i.e., the area under the concentration-time curve over 24 h in the steady state divided by the MIC] are 46 to 86 for moxifloxacin and 74 to 258 for levofloxacin). A comparative efficacy trial in the rabbit model of active TB demonstrated the superiority of moxifloxacin in reducing bacterial burden at the lesion level and in sterilizing cellular and necrotic lesions. Collectively, these results show that PK/PD data obtained at the site of infection represent an adequate predictor of drug efficacy against TB and constitute the baseline required to explore synergies, antagonism, and drug-drug interactions in fluoroquinolone-containing regimens.

Original languageEnglish
Article numbere02516-18
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number5
DOIs
StatePublished - May 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Fluoroquinolone
  • Lesion-centric pharmacology
  • MDR-TB
  • Moxifloxacin
  • Tuberculosis

Fingerprint

Dive into the research topics of 'Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations'. Together they form a unique fingerprint.

Cite this